Fig. 6: Subset analysis for fluoxetine treatment effects.

A Pathways identified as significantly enriched (q < 0.05) across the 13 comparisons of treatment effects in MDD patients or stressed rodent models. B Percentage of pathways significantly affected by fluoxetine treatment in MDD patients or stressed rodent models from each of the Reactome categories (“Top Level”) or KEGG Database. C Density plot showing distribution of Vote Sums across pathways, colored by meta-analysis result. Positive scores indicate increased expression with fluoxetine. D Overlap of pathways identified as statistically significant by Max-P meta-analysis of treated vs. untreated samples in stressed rodents or depressed patients, in unstressed rodents, and pathways identified by interaction analysis comparing fluoxetine effects in stressed vs. unstressed mice. E q-value by Max-P and Vote Sums for pathways identified as significant across the 13 comparisons in MDD patients or stressed rodents (q < 0.05 by Max-P), subset to include only pathways also enriched by Freq50 (p < 0.05 in greater than half of comparisons). F Network diagram showing similarity between pathways, with labels provided in E.